|
de la Morena-Barrio ME, Corral J, Lopez-Garcia C, Jimenez-Diaz VA, Minano A, Juan-Salvadores P, Esteve-Pastor MA, Baz-Alonso JA, Rubio AM, Sarabia-Tirado F, Garcia-Navarro M, Garcia-Lara J, Marin F, Vicente V, Pinar E, Canovas SJ, de la Morena G. Contact pathway in surgical and transcatheter aortic valve replacement. Front Cardiovasc Med. 2022 Jul 22;9:887664. doi: 10.3389/fcvm.2022.887664. eCollection 2022. PubMed PMID: 35935621; PubMed Central PMCID: PMC9354960.
AÑO: 2022; IF: 3.6
|
35935621
|
Esteve-Pastor MA, Rivera-Caravaca JM, Roldan V, Sanmartin Fernandez M, Arribas F, Masjuan J, Barrios V, Cosin-Sales J, Freixa-Pamias R, Recalde E, Perez-Cabeza AI, Manuel Vazquez Rodriguez J, Rafols Priu C, Anguita Sanchez M, Lip GYH, Marin F. Predicting performance of the HAS-BLED and ORBIT bleeding risk scores in patients with atrial fibrillation treated with Rivaroxaban: Observations from the prospective EMIR Registry. Eur Heart J Cardiovasc Pharmacother. 2022 Dec 15;9(1):38-46. doi: 10.1093/ehjcvp/pvac060. PubMed PMID: 36318457.
AÑO: 2022; IF: 7.1
|
|
Esteve-Pastor MA, Rivera-Caravaca JM, Ruiz-Ortiz M, Muniz J, Roldan-Rabadan I, Otero D, Lopez-Galvez R, Cequier A, Bertomeu-Martinez V, Badimon L, Anguita M, Lip GYH, Marin F; FANTASIIA investigators. A comparison of front-line oral anticoagulants for the treatment of non-valvular atrial fibrillation: effectiveness and safety of direct oral anticoagulants in the FANTASIIA registry. Expert Opin Pharmacother. 2022 Aug;23(12):1457-1465. doi: 10.1080/14656566.2022.2109961. Epub 2022 Aug 12. PubMed PMID: 35924672.
AÑO: 2022; IF: 3.2
|
|
Esteve-Pastor MA, Ruiz-Ortiz M, Muniz J, Roldan-Rabadan I, Otero D, Cequier A, Bertomeu-Martinez V, Badimon L, Anguita M, Lip GYH, Marin F. Impact of Integrated Care Management on Clinical Outcomes in Atrial Fibrillation Patients: A Report From the FANTASIIA Registry. Front Cardiovasc Med. 2022 May 2;9:856222. doi: 10.3389/fcvm.2022.856222. eCollection 2022. PubMed PMID: 35586656; PubMed Central PMCID: PMC9108173.
AÑO: 2022; IF: 3.6
|
|
Sanmartin Fernandez M, Anguita Sanchez M, Arribas F, Baron-Esquivias G, Barrios V, Cosin-Sales J, Esteve-Pastor MA, Freixa-Pamias R, Lekuona I, Perez-Cabeza AI, Urena I, Vazquez Rodriguez JM, Rafols Priu C, Marin F. Outcomes and predictive value of the 2MACE score in patients with atrial fibrillation treated with rivaroxaban in a prospective, multicenter observational study: The EMIR study. Cardiol J. 2022;29(4):601-609. doi: 10.5603/CJ.a2022.0044. Epub 2022 May 27. PubMed PMID: 35621092; PubMed Central PMCID: PMC9273239.
AÑO: 2022; IF: 2.9
|